// App-Quantinova.ai

: Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1-like Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Haiping Dai

Principal Investigators

  • Wei Cui

  • Hongjie Shen

  • Qian Wang

  • Jia Yin

  • Zheng Li

  • Depei Wu

  • Xiaowen Tang

Medical Centers

  • Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China

  • National Clinical Research Center for Hematologic Diseases, Suzhou, China

  • Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, Suzhou, China

  • Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou, China

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • L-Tyrosine

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved